Filtered By:
Drug: Lovenox

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 96 results found since Jan 2013.

Edoxaban versus enoxaparin –warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
Publication date: Available online 30 August 2016 Source:The Lancet Author(s): Andreas Goette, Jose L Merino, Michael D Ezekowitz, Dmitry Zamoryakhin, Michael Melino, James Jin, Michele F Mercuri, Michael A Grosso, Victor Fernandez, Naab Al-Saady, Natalya Pelekh, Bela Merkely, Sergey Zenin, Mykola Kushnir, Jindrich Spinar, Valeriy Batushkin, Joris R de Groot, Gregory Y H Lip Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled enoxaparin–warfarin therapy. Few safety d...
Source: The Lancet - August 30, 2016 Category: Journals (General) Source Type: research

Efficacy and safety of rivaroxaban thromboprophylaxis after arthroplasty of the hip or knee: retrospective cohort study.
Conclusions Rivaroxaban is an effective and safe anticoagulant for thromboprophylaxis after hip arthroplasty or knee arthroplasty if used in a modified regimen involving enoxaparin administered in the inpatient setting followed by rivaroxaban upon hospital discharge. PMID: 27580310 [PubMed - in process]
Source: Annals of the Royal College of Surgeons of England - August 31, 2016 Category: Surgery Authors: Loganathan L, Hua A, Patel S, Gibbons C, Vizcaychipi MP Tags: Ann R Coll Surg Engl Source Type: research

Anticoagulation prescribing patterns in patients with cancer
The objective of this retrospective cohort was to describe real-world anticoagulation prescribing patterns in cancer patients at a large academic medical center between January 1, 2013 and October 31, 2016. We sought to assess the safety, tolerability, and efficacy of DOACs in patients with cancer for either VTE and/or AF. Patient demographic, clinical characteristics, as well as bleeding and thrombotic events were collected. There were 214 patients in our analysis, of which 71 patients (33%) received a DOAC [apixaban (n  = 22), dabigatran (n = 17), and rivaroxaban (n = 32)]. There were fewer bleeding events an...
Source: Journal of Thrombosis and Thrombolysis - October 19, 2017 Category: Hematology Source Type: research

E-082 Aggressive endovascular management of massive dural venous sinus thrombosis in the setting of acute myelogenous leukemia
Conclusion DVST is an uncommon cause of stroke. The appropriate diagnosis is imperative as the treatment for DVS is vastly different from the treatment of arterial stroke. Patients who suffer from DVST have a good prognosis and often achieve complete recovery. This case demonstrates the utility of more invasive endovascular treatments for extreme cases that fail to improve, or worsen, following a trial of conventional care. When thrombolysis and thrombectomy alone were not successful, stenting of an underlying dural sinus stenosis was ultimately required for successful recanalization. Disclosures: D. Leonard: None. A. Ha...
Source: Journal of NeuroInterventional Surgery - July 23, 2017 Category: Neurosurgery Authors: Leonard, D., Haider, A., Thakur, R., Gottlich, C., Khan, U., Layton, K. Tags: Electronic Poster Abstracts Source Type: research

Reversal of Anticoagulation: Therapeutic Advances and Clinical Guidelines
Background: Anticoagulants are life-saving medications that prevent and treat thromboembolic disease and are of particular importance in the elderly population for prevention of stroke in atrial fibrillation. The advent of direct oral anticoagulants and reversal agents has yielded more options for patients, although complicating clinical decision-making. Areas of Uncertainty: The decision to anticoagulate in atrial fibrillation depends on the risks of stroke versus bleeding. The accompanying HAS-BLED score for predicting bleeding allows an estimation of net clinical benefit. Despite these tools, uncertainty remains. N...
Source: American Journal of Therapeutics - January 1, 2018 Category: Drugs & Pharmacology Tags: Systematic Review and Clinical Guidelines Source Type: research

Is There Any Relationship between TSH Levels and Prognosis in Acute Coronary Syndrome?
Conclusions: In patients with acute coronary syndromes and TSH> 4 mIU/L at admission, worse prognosis was observed, with higher incidences of in-hospital combined events, cardiogenic shock and bleeding.Resumo Fundamento: Estudos pequenos t êm relacionado níveis mais elevados de hormônio tireoestimulante (TSH) a pior prognóstico em pacientes com síndrome coronariana aguda (SCA). Tal relação, no entanto, permanece incerta. Objetivo: Analisar os desfechos de pacientes com SCA, relacionando-os aos níveis de TSH medidos no setor d e emergência. Métodos: Estudo retrospectivo observacional incluindo 505 pacientes com...
Source: Arquivos Brasileiros de Cardiologia - March 19, 2018 Category: Cardiology Source Type: research

Safety and efficacy of a new thromboprophylaxis regiment for total knee and total hip replacement: a retrospective cohort study in 265 patients.
Conclusion: The regimen consisting of sequential enoxaparin and rivaroxaban is associated with a significant bleeding risk, although the risk of patients requiring a return to theatre is low. Further prospective trials are required to compare the safety and efficacy profiles of this regimen with established thromboprophylaxis regimens. PMID: 30123323 [PubMed]
Source: Patient Safety in Surgery - August 22, 2018 Category: Surgery Authors: Fallaha MA, Radha S, Patel S Tags: Patient Saf Surg Source Type: research

Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial
ConclusionIn ENSURE-AF, thromboembolic events were rare and absolute bleeding event rates were higher with concomitant APT. These findings may be relevant for AF-patients considered for dual therapy; even for a short treatment duration of 1  month.
Source: Clinical Research in Cardiology - March 30, 2020 Category: Cardiology Source Type: research

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Enoxaparin sodium/warfarin: Maternal stroke and fetal warfarin syndrome: 2 case reports
Source: Reactions - February 26, 2013 Category: Drugs & Pharmacology Tags: Short communication Source Type: research

Acute pulmonary emboli in a patient on long-term dabigatran therapy.
CONCLUSIONS: Our patient developed acute bilateral PE despite receiving long-term anticoagulation with dabigatran. While it is possible that patient-specific factors resulted in reduced dabigatran exposure and efficacy, conclusions cannot be made. PMID: 23535815 [PubMed - in process]
Source: The Annals of Pharmacotherapy - April 1, 2013 Category: Drugs & Pharmacology Authors: Rafferty JA, Prom R, Kujawski SZ Tags: Ann Pharmacother Source Type: research

Enoxaparin sodium/warfarin: Maternal stroke and fetal warfarin syndrome: 2 case reports
Source: Reactions - October 13, 2013 Category: Drugs & Pharmacology Tags: Short communication Source Type: research

Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials
ConclusionRivaroxaban is associated with a significantly lower risk of MI in a broad spectrum of patients when tested against different controls.
Source: Coronary Artery Disease - November 8, 2013 Category: Cardiology Tags: Original Research Source Type: research

Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation
Conclusions: LMWH in the setting of LVAD shows rapid and constant biologic efficacy. Anti-coagulation with LMWH appears feasible after LVAD implantation. These findings support further evaluation of LMWH as an alternative to unfractionated heparin in this patient cohort.
Source: The Journal of Heart and Lung Transplantation - October 28, 2013 Category: Transplant Surgery Authors: Sigrid E. Sandner, Julia Riebandt, Thomas Haberl, Stephane Mahr, Angela Rajek, Heinrich Schima, George M. Wieselthaler, Guenther Laufer, Daniel Zimpfer Tags: Featured Articles Source Type: research